- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for modern biomarker and drug development in oncology
Authors
Keywords
Biomarkers, Drug development, Targeted therapies
Journal
Journal of Hematology & Oncology
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-10-02
DOI
10.1186/s13045-014-0070-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA
- (2015) John A. Martignetti et al. NEOPLASIA
- Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
- (2014) Edward Rosfjord et al. BIOCHEMICAL PHARMACOLOGY
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
- (2014) Robert J. Motzer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
- (2014) Mary Jo Fackler et al. CANCER RESEARCH
- A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
- (2014) Jian Zhang et al. Journal of Hematology & Oncology
- Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
- (2014) Vivek Subbiah et al. Journal of Hematology & Oncology
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group
- (2014) Jacqueline Anne Hall et al. LANCET ONCOLOGY
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Cancer drivers everywhere?
- (2014) Darren J. Burgess NATURE REVIEWS GENETICS
- The impact of whole-genome sequencing on the reconstruction of human population history
- (2014) Krishna R. Veeramah et al. NATURE REVIEWS GENETICS
- Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
- (2014) B. Dreno et al. ONCOLOGIST
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Proteomics for discovery of candidate colorectal cancer biomarkers
- (2014) Paula Álvarez-Chaver WORLD JOURNAL OF GASTROENTEROLOGY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib
- (2014) X. Luo et al. Cancer Discovery
- Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives
- (2013) Ana Custodio et al. CANCER TREATMENT REVIEWS
- Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA
- (2013) J. Maier et al. CLINICAL CANCER RESEARCH
- Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
- (2013) M. B. Shea et al. CLINICAL CANCER RESEARCH
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
- (2013) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
- (2013) Scott A. Laurie et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
- (2013) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
- (2013) Akash K. Kaushik et al. JOURNAL OF PROTEOME RESEARCH
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
- (2013) Fred R. Hirsch et al. Journal of Thoracic Oncology
- EGFR-directed treatments in SCCHN
- (2013) Everett E Vokes et al. LANCET ONCOLOGY
- Adjuvant bevacizumab: positive data from a negative trial
- (2013) Jose Perez-Garcia et al. LANCET ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Translating metastasis-related biomarkers to the clinic—progress and pitfalls
- (2013) François-Clément Bidard et al. Nature Reviews Clinical Oncology
- Implementing personalized cancer genomics in clinical trials
- (2013) Richard Simon et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular genetic testing and the future of clinical genomics
- (2013) Sara Huston Katsanis et al. NATURE REVIEWS GENETICS
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?
- (2013) Michael J. Morris et al. SEMINARS IN ONCOLOGY
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Adjuvant therapy in primary GIST: state-of-the-art
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Antibody-Drug Conjugates for the Treatment of Cancer
- (2012) John A. Flygare et al. Chemical Biology & Drug Design
- 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
- (2012) K. Herrmann et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
- (2012) C. Giessen et al. CLINICAL CANCER RESEARCH
- Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer
- (2012) R. Ferraldeschi et al. CLINICAL CHEMISTRY
- Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
- (2012) Joo Ern Ang et al. CURRENT DRUG TARGETS
- Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour
- (2012) Heikki Joensuu DRUGS
- 409 Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy
- (2012) B. Irving et al. EUROPEAN JOURNAL OF CANCER
- Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays
- (2012) Liping Chung et al. Expert Review of Proteomics
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Quantitative assessment of dynamic PET imaging data in cancer imaging
- (2012) Mark Muzi et al. MAGNETIC RESONANCE IMAGING
- Promise and pitfalls of quantitative imaging in oncology clinical trials
- (2012) Brenda F. Kurland et al. MAGNETIC RESONANCE IMAGING
- Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery
- (2012) Paola Indovina et al. MASS SPECTROMETRY REVIEWS
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
- (2012) C. M. Lovly et al. Science Translational Medicine
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)
- (2012) Toni K. Choueiri et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
- (2011) Matthew G. Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
- (2011) Jeeyun Lee et al. JNCI-Journal of the National Cancer Institute
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Deep proteome and transcriptome mapping of a human cancer cell line
- (2011) N. Nagaraj et al. Molecular Systems Biology
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diffusion and Diffusion Tensor Imaging in Brain Cancer
- (2011) Elizabeth R. Gerstner et al. SEMINARS IN RADIATION ONCOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform
- (2010) Daniel Summerer et al. GENOMICS
- A window into third-generation sequencing
- (2010) E. E. Schadt et al. HUMAN MOLECULAR GENETICS
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Awakening Immunity
- (2010) H. Schreiber et al. SCIENCE
- Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy
- (2009) Jian-Mei Hou et al. AMERICAN JOURNAL OF PATHOLOGY
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications
- (2009) Marwan K Tayeh et al. GENETICS IN MEDICINE
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Fundamentals of Quantitative Dynamic Contrast-Enhanced MR Imaging
- (2009) Michael J. Paldino et al. Magnetic Resonance Imaging Clinics of North America
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
- (2009) Arun Sreekumar et al. NATURE
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Basic Principles and Technologies for Deciphering the Genetic Map of Cancer
- (2009) Georgios Voidonikolas et al. WORLD JOURNAL OF SURGERY
- Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
- (2008) Christopher L. Corless et al. Annual Review of Pathology-Mechanisms of Disease
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Microarray Technology and Applications in the Arena of Genome-Wide Association
- (2008) S. F. A. Grant et al. CLINICAL CHEMISTRY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer
- (2008) Ji-Youn Han et al. Journal of Thoracic Oncology
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search